LDS/Medical Tests/Wilson Disease, (ATP7B) Gene Mutation Analysis

Wilson Disease, (ATP7B) Gene Mutation Analysis

Wilson disease is a progressive autosomal recessive disease caused by mutations in the ATP7B gene, located on the long arm (q) of chromosome 13. This gene codes for the protein copper-transporting ATPase 2 (Cu-ATPases). This is part of the P-type ATPase family responsible for transporting metals into and out of cells and is found mainly in hepatocyte Golgi apparatus where it transfers copper to a protein called ceruloplasmin.

Defective Cu-ATPase leads to progressive accumulation of hepatocyte copper; this eventually spills into the systemic circulation affecting other organs in addition to the liver.

More than 300 mutations have been identified in the 80 kb ATP7B gene, with the H1069Q, L936X and 2532delA mutations being the most frequent; however, specific mutation frequency varies by geographic region. It is estimated that 1 in 30,000 people are affected by Wilson disease, while carrier incidence is approximately 1 in 90. Wilson disease has an increased prevalence in individuals from China, Japan, and Sardinia (with different mutations being more prevalent in each area). The resulting protein defects cause deposition of copper in the liver, brain, kidneys, and eyes leading to tissue damage and scarring. Patients often present with variable hepatic disease, neuropsychiatric symptoms, and characteristic (but not specific) ophthalmologic findings (Kaiser- Fleischer ring). Wilson disease should be considered in the differential of a patient presenting with primary unexplained liver disease, neurologic symptoms or psychiatric dysfunction. Prompt diagnosis and treatment with chelation therapy is imperative for avoidance of long term, permanent organ damage.

  • Confirmation of Wilson disease for symptomatic individuals
  • Carrier testing for first degree relatives and siblings of affected individuals
  • Testing for patients under the age of 40 with unexplained liver disease
  • Testing for patients with unexplained neurological disease or psychiatric dysfunction, especially in association with liver disease

Homozygous or compound heterozygote *ATP7B* gene mutation confirms a diagnosis of Wilson disease. Heterozygous ATP7B gene mutation confirms carrier status.

Negative result does not exclude the possibility of Wilson disease, or positive carrier status. Rare polymorphisms exist and may result in false negative or false positive results. Certain types of mutations may not be identified, such as large genomic deletions and promoter mutations.

Negative for mutations analyzed (Mutation not detected)

Real Time Polymerase Chain Reaction (PCR) with ARMS or allele specific primer extension (ASPE), Conventional sequencing, Next generation sequencing (NGS).

Whole blood collected in EDTA (purple top tube) or ACD (blue top tube).

Stability

  • Ambient: up to 3-5 days
  • Refrigerated: up to 5-7 days
Liver copper analysis, Aspartate aminotransferase (AST), Alanine Transaminase (ALT), Alkaline Phosphatase (ALP), Alkaline phosphatase to bilirubin ratio, Hemoglobin/hematocrit, Complete Blood Count (CBC) with manual diff, INR, Total and conjugated bilirubin, Albumin, Serum copper (Cu), Serum ceruloplasmin (CP), 24-hour urine Cu, Direct Coombs test. Liver biopsy may be useful when discrepancies between biochemical results or molecular results exist.
3-10 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login